Development and Validation of an Immuno-PET Tracer as a Companion Diagnostic Agent for Antibody-Drug Conjugate Therapy to Target the CA6 Epitope
Authors:
- 1 July 2015
- journal article
- research article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 276 (1) , 191-198
Abstract
The antibody fragment 64Cu-DOTA-B-Fab showed high binding affinity and stability and a promising ability to allow differentiation between CA6-positive and CA6-negative tumors in vivo at early time points after injection, suggesting that it may be a successful companion diagnostic agent for antibody-drug conjugate therapy. Purpose To develop and compare three copper 64 (64Cu)–labeled antibody fragments derived from a CA6-targeting antibody (huDS6) as immuno-positron emission tomography (immuno-PET)–based companion diagnostic agents for an antibody-drug conjugate by using huDS6. Materials and Methods Three antibody fragments derived from huDS6 were produced, purified, conjugated to 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA), and evaluated in the following ways: (a) the affinity of the fragments and the DOTA conjugates was measured via flow cytometry, (b) the stability of the labeled fragments was determined ex vivo in human serum over 24 hours, and (c) comparison of the in vivo imaging potential of the fragments was evaluated in mice bearing subcutaneous CA6-positive and CA6-negative xenografts by using serial PET imaging and biodistribution. Isotype controls with antilysozyme and anti-DM4 B-Fabs and blocking experiments with an excess of either B-Fab or huDS6 were used to determine the extent of the ant...Keywords
This publication has 18 references indexed in Scilit:
- Comparison of 64Cu-Complexing Bifunctional Chelators for Radioimmunoconjugation: Labeling Efficiency, Specific Activity, and in Vitro/in Vivo StabilityBioconjugate Chemistry, 2012
- Maytansine and Cellular Metabolites of Antibody-Maytansinoid Conjugates Strongly Suppress Microtubule Dynamics by Binding to MicrotubulesMolecular Cancer Therapeutics, 2010
- The Path to Personalized MedicineNew England Journal of Medicine, 2010
- Tumor targeting of functionalized lipid nanoparticles: Assessment by in vivo fluorescence imagingEuropean Journal of Pharmaceutics and Biopharmaceutics, 2010
- Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast CancerClinical Pharmacology & Therapeutics, 2010
- The role of companion diagnostics in the development and use of mutation-targeted cancer therapiesNature Biotechnology, 2006
- Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applicationsProtein Engineering, Design and Selection, 2004
- Monoclonal antibody DS6 detects a tumor-associated sialoglycotope expressed on human serous ovarian carcinomasInternational Journal of Cancer, 2000
- The propagation of binding interactions to remote sites in proteins: Analysis of the binding of the monoclonal antibody D1.3 to lysozymeProceedings of the National Academy of Sciences, 1999
- A therapeutic trial of maytansine.1978